Quantitative analysis of sponsorship bias in economic studies of antidepressants

CB Baker, MT Johnsrud, ML Crismon… - The British Journal of …, 2003 - cambridge.org
BackgroundConcern is widespread about potential sponsorship influence on research,
especially in pharmacoeconomic studies. Quantitative analysis of possible bias in such …

Escitalopram: a pharmacoeconomic review of its use in depression

KF Croom, GL Plosker - Pharmacoeconomics, 2003 - Springer
Escitalopram (Cipralex®), a new highly selective serotonin reuptake inhibitor (SSRI), is the
active S-enantiomer of RS-citalopram. It is effective in the treatment of patients with major …

SNRIs versus SSRIs: mechanisms of action in treating depression and painful physical symptoms

N Sussman - Prim Care Companion J Clin Psychiatry, 2003 - psychiatrist.com
Patients with depression frequently experience painful somatic symptoms, which may be the
only symptoms reported to the physician. In addition, patients with chronic painful medical …

[HTML][HTML] Venlafaxin ist kein SSRI, sondern ein SNRI, und das ist relevant

J Fritze, B Schneider, B Weber - psychoneuro, 2003 - thieme-connect.com
Venlafaxin ist ein selektives Antidepressivum, indem es-wie selektiv-serotonerge
Antidepressiva (SSRI)-frei von den anticholinergen, antihistaminergen, antiadrenergen und …

[DOC][DOC] EVALUATION PHARMACOECONOMIQUE DES RECURRENCES DEPRESSIVES

R Launois, S Payet - EVALUATION, 2003 - researchgate.net
La dépression majeure se caractérise par l'existence durant au moins quinze jours d'une
humeur dépressive et/ou d'une perte d'intérêt ou du plaisir dans la plupart des activités …